Author Identifier

Daniel A Galvao

ORCID : 0000-0002-8209-2281

Robert U Newton

ORCID : 0000-0003-0302-6129

Document Type

Journal Article

Publication Title

Cancers

Volume

13

Issue

23

Publisher

MDPI

School

School of Medical and Health Sciences / Exercise Medicine Research Institute / Centre for Exercise and Sports Science Research

RAS ID

40502

Funders

Australian New Zealand Urogenital and Prostate Cancer Trails Groupd Below the Belt research grant Commonwealth Research Training Program scholarship Freemasons Centre for Men's Health National Health and Medical Research Council Victorian Cancer Agency

Grant Number

NHMRC Number : 1090517

Grant Link

http://purl.org/au-research/grants/nhmrc/1090517

Comments

Evans, H. E. L., Galvão, D. A., Forbes, C. C., Girard, D., Vandelanotte, C., Newton, R. U., . . . Short, C. E. (2021). Acceptability and preliminary efficacy of a web-and telephone-based personalised exercise intervention for individuals with metastatic prostate cancer: The exerciseguide pilot randomised controlled trial. Cancers, 13(23), article 5925. https://doi.org/10.3390/cancers13235925

Abstract

Preliminary research has shown the effectiveness of supervised exercise-based interventions in alleviating sequela resulting from metastatic prostate cancer. However, many individuals encounter barriers that limit the uptake of face-to-face exercise. Technology-enabled interventions offer a distance-based alternative. This pilot study aimed to explore the acceptability, safety and preliminary efficacy of a web-based exercise intervention (ExerciseGuide) in individuals with metastatic prostate cancer. Forty participants (70.2 ± 8.5 years) with metastatic prostate cancer were randomised into the 8-week intervention (N = 20) or a wait-list control (N = 20). The intervention arm had access to a computer-tailored website, personalised exercise prescription and remote supervision. ExerciseGuide was deemed acceptable with a score ≥ 20 on the client satisfaction questionnaire; however, the usability score was just below the pre-specified score of ≥ 68 on the software usability scale. There were no serious adverse events reported. Moderate-to-vigorous physical activity levels between baseline and follow-ups were significantly higher (10.0 min per day; 95% CI = (1.3–18.6); p = 0.01) in the intervention group compared to wait-list control. There were also greater improvements in step count (1332; 95% CI = (159–2505); p = 0.02) and identified motivation (0.4, 95% CI = (0.0, 0.7); p = 0.04). Our findings provide preliminary evidence that ExerciseGuide is acceptable, safe and efficacious among individuals with metastatic prostate cancer.

DOI

10.3390/cancers13235925

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Research Themes

Health

Priority Areas

Prevention, detection and management of cancer and other chronic diseases

Share

 
COinS